Brainomix与TIPAL试验合作评估其在肺部疾病中的新型IPF生物标志物-动脉网

Brainomix Partners with TIPAL Trial to Assess Its Novel IPF Biomarker in Lung Disease

biospace 等信源发布 2023-09-09 03:38



可切换为仅中文







The company will apply its cutting-edge AI technology to run a sub-study assessing the value of its novel imaging biomarkers

该公司将应用其尖端的人工智能技术进行子研究，评估其新型成像生物标志物的价值

OXFORD, UK, 8th September 2023 – Brainomix announced today that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform. The TIPAL trial, funded by the National Institute of Health Research (NIHR) and sponsored by the Norfolk and Norwich University Hospitals (NNUH) NHS Foundation Trust, is a placebo-controlled 52-week multi-centre study that is evaluating the impact of lansoprazole – a commonly prescribed medication for indigestion, heartburn and acid reflux – on patients with a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF).

英国牛津，2023年9月8日-Brainomix今天宣布，他们将与TIPAL试验组合作开展一项子研究，以评估其开创性的e-Lung平台的功效。TIPAL试验由美国国立卫生研究院（NIHR）资助，由诺福克和诺维奇大学医院（NNUH）NHS基金会信托基金赞助，是一项安慰剂对照的为期52周的多中心研究，正在评估兰索拉唑-一种常用的消化不良药，胃灼热和酸反流–确诊为特发性肺纤维化（IPF）的患者。

IPF is a condition marked by relentless decline in lung function, but with a variable disease trajectory..

IPF是一种以肺功能无情下降为特征的疾病，但疾病轨迹可变。。

The 298 patients expected to be enrolled in the trial will perform home spirometry tests to measure their forced vital capacity (FVC). Daily assessments taken at baseline and 12 months post-randomisation will be compared to assess the impact of lansoprazole on absolute change in percent predicted FVC.

预计将参加试验的298名患者将进行家庭肺活量测定测试以测量其用力肺活量（FVC）。将比较基线和随机分组后12个月的每日评估，以评估兰索拉唑对预测FVC百分比绝对变化的影响。

Participants will complete weekly spirometry assessments at home during follow-up..

随访期间，参与者将在家中每周完成肺活量测定评估。。

The Brainomix sub-study will be run in parallel using the Oxford-based company’s e-Lung platform, an AI-powered image processing module and tool that standardizes the quantification of lung fibrosis on High Resolution (HR) CT scans to more accurately identify progressive fibrosis patients. At the core of this platform is a novel imaging biomarker, the weighted reticulovascular (WRV) score, which quantifies the extent of the lung affected by reticulovascular abnormalities, and has been shown to provide superior prognostic value compared with traditional measures.

Brainomix子研究将使用基于牛津的公司的e-Lung平台并行运行，该平台是一种AI驱动的图像处理模块和工具，可在高分辨率（HR）CT扫描中标准化肺纤维化的量化，以更准确地识别进行性纤维化耐心。该平台的核心是一种新型成像生物标志物，加权网状血管（WRV）评分，用于量化受网状血管异常影响的肺部程度，并且与传统测量方法相比，已被证明具有优越的预后价值。

The primary aim of the sub-study is to determine the difference in change (between baseline and 12 months post-randomization) in WRV score between treatment with lansoprazole and placebo..

该子研究的主要目的是确定兰索拉唑和安慰剂治疗之间WRV评分变化（基线和随机化后12个月之间）的差异。。

“We are excited to have the opportunity to collaborate with the TIPAL study group, and to incorporate our pioneering AI technology into a prospective trial to help assess the efficacy of lansoprazole in IPF patients,” noted Dr Peter George, Senior Medical Director at Brainomix and Clinical Lead for ILD at Royal Brompton Hospital in London.

Brainomix高级医疗总监Peter George博士指出：“我们很高兴有机会与TIPAL研究小组合作，并将我们开创性的AI技术纳入前瞻性试验，以帮助评估兰索拉唑在IPF患者中的疗效。”伦敦皇家布朗普顿医院ILD临床领导。

“We are highly motivated by the potential to harness our technology in a way that helps to speed up clinical trials, identify more effective drugs, and improve the lives of IPF patients.”.

“我们非常有动力以有助于加快临床试验，确定更有效的药物并改善IPF患者生活的方式利用我们的技术。”。

Professor Andrew Wilson, TIPAL Chief Investigator, said “It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study. Not only will this venture tell whether lansoprazole improves the scarring detected on CT scans, but it will allow us to compare CT scan abnormalities to home-based lung function tests”..

TIPAL首席研究员Andrew Wilson教授说：“很有机会将Brainomix开发的尖端CT扫描技术纳入TIPAL研究。不仅可以判断兰索拉唑是否能改善CT扫描中检测到的瘢痕形成，但它将允许我们将CT扫描异常与基于家庭的肺功能测试进行比较“。。

More information about the TIPAL study, the UK’s largest government funded pulmonary fibrosis trial, can be found at https://www.uea.ac.uk/web/groups-and-centres/projects/tipal

有关英国最大的政府资助的肺纤维化试验TIPAL研究的更多信息，请参阅https://www.uea.ac.uk/web/groups-and-centres/projects/tipal

This study is funded by the NIHR Health Technology Assessment programme (NIHR127479). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

本研究由NIHR健康技术评估计划（NIHR127479）资助。所表达的观点是作者的观点，不一定是NIHR或卫生和社会保健部的观点。

-Ends-

-结束-

About Brainomix

关于Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide.

Brainomix专门致力于创建AI软件解决方案，以实现精准医学在中风，肺纤维化和癌症中做出更好的治疗决策。Brainomix起源于牛津大学，是一家不断扩大的商业阶段公司，创新了在全球30多个国家使用的获奖成像生物标志物和软件解决方案。

Its first product, the Brainomix 360 platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients..

它的第一款产品Brainomix 360平台为临床医生提供最全面的中风成像解决方案，加快治疗时间并提高患者的功能独立性。。

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

要了解有关Brainomix及其技术的更多信息，请访问www.Brainomix.com，并在Twitter，LinkedIn和Facebook上关注我们。

Contacts

联络

Jeff Wyrtzen, Chief Marketing & Business Development Officer

Jeff Wyrtzen，首席营销和业务开发官员

jwyrtzen@brainomix.com

M +44 (0)7927 164210

M+44（0）7927164210

T +44 (0)1865 582730

T+44（0）1865582730